nach oben

Archives of Gynecology and Obstetrics

Erschienen in:

13.02.2019 | Gynecologic Oncology

High Ki-67 expression is significantly associated with poor prognosis of ovarian cancer patients: evidence from a meta-analysis

verfasst von: Dongmei Qiu, Wanqiu Cai, Zhiqiao Zhang, Hongyan Li, Dongmei Zhou

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Objective

The prognostic significance of Ki-67 expression in patients with ovarian cancer was controversial in various studies. Therefore, we carried out a meta-analysis to determine the prognostic significance of Ki-67 in ovarian cancer patients.

Methods

We searched PubMed, Cochrane Library, EMBASE, Web of Knowledge, China National Knowledge Infrastructure database and WanFang digital database for eligible studies from January 1, 1990 to June 1, 2017. The pooled hazard ratios and 95% confidence intervals were calculated to assess the prognostic significance of Ki-67 expression for overall survival in ovarian cancer patients.

Results

Finally, 38 eligible studies and 5004 ovarian cancer patients were included in the current study. The pooled hazard ratio was 1.35 (95% confidence interval 1.24–1.46, P = 0.001) for overall survival in ovarian cancer patients. The funnel plot bias was obviously asymmetrical and Egger’s test also detected significant publication bias (P = 0.001). The Contour-enhanced funnel plot with trim-and-fill method supplemented 11 dummy studies to balance the funnel plot and nine new supplementary studies were in area with statistical significance. Sensitivity analysis and cumulative meta-analysis further demonstrated that the association between high Ki-67 expression and poor overall survival of ovarian cancer patients was stable and reliable.

Conclusions

High Ki-67 expression is significantly related to poor overall survival and may serve as a prognostic biomarker for ovarian cancer patients.

Nur mit Berechtigung zugänglich

Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30CrossRefPubMed

Bast RC Jr, Hennessy B, Mills GB (2009) The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9:415–428CrossRefPubMedPubMedCentral

Schluter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD et al (1993) The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 123:513–522CrossRefPubMed

Cattoretti G, Becker MH, Key G, Duchrow M, Schluter C, Galle J et al (1992) Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168:357–363CrossRefPubMed

Felix AS, Sherman ME, Hewitt SM, Gunja MZ, Yang HP, Cora RL et al (2015) Cell-cycle protein expression in a population-based study of ovarian and endometrial cancers. Front Oncol 5:25CrossRefPubMedPubMedCentral

Hua M, Yan S, Deng Y, Xi Q, Liu R, Yang S et al (2015) CAP1 is overexpressed in human epithelial ovarian cancer and promotes cell proliferation. Int J Mol Med 35:941–949CrossRefPubMedPubMedCentral

Deng Y, Chen C, Hua M, Xi Q, Liu R, Yang S et al (2015) Annexin A2 plays a critical role in epithelial ovarian cancer. Arch Gynecol Obstet 292:175–182CrossRefPubMed

Battista MJ, Mantai N, Sicking I, Cotarelo C, Weyer V, Lebrecht A et al (2014) Ki-67 as an independent prognostic factor in an unselected cohort of patients with ovarian cancer: results of an explorative, retrospective study. Oncol Rep 31:2213–2219CrossRefPubMed

Vallen MJ, Massuger LF, Ten DG, Bulten JV, Kuppevelt TH (2012) Highly sulfated chondroitin sulfates, a novel class of prognostic biomarkers in ovarian cancer tissue. Gynecol Oncol 127:202–209CrossRefPubMed

10.

Kim H, Kim K, No JH, Jeon YT, Jeon HW, Kim YB (2012) Prognostic value of biomarkers related to drug resistance in patients with advanced epithelial ovarian cancer. Anticancer Res 32:589–594CrossRefPubMed

11.

Lu M, Xiang J, Xu F, Wang Y, Yin Y, Chen D (2012) The expression and significance of pThr32-FOXO3a in human ovarian cancer. Med Oncol 29:1258–1264CrossRefPubMed

12.

Lee JS, Choi YD, Choi C, Lee MC, Park CS, Min KW (2005) Expression of PTEN in ovarian epithelial tumors and its relation to tumor behavior and growth. Anal Quant Cytol Histol 27:202–210PubMed

13.

Khalifeh I, Munkarah AR, Schimp V, Morris R, Lawrence WD, Ali-Fehmi R (2005) The impact of c-kit and ki-67 expression on patients prognosis in advanced ovarian serous carcinoma. Int J Gynecol Pathol 24:228–234CrossRefPubMed

14.

Ali-Fehmi R, Morris RT, Bandyopadhyay S, Che M, Schimp V, Malone JM et al (2005) Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival. Am J Obstet Gynecol 192:819–825CrossRefPubMed

15.

Nakayama K, Takebayashi Y, Hata K, Fujiwaki R, Iida K, Fukumoto M et al (2004) Allelic loss at 19q12 and Xq11-12 predict an adverse clinical outcome in patients with mucinous ovarian tumours of low malignant potential. Br J Cancer 90:1204–1210CrossRefPubMedPubMedCentral

16.

Layfield LJ, Saria EA, Berchuck A, Dodge RK, Thompson JK, Conlon DH et al (1997) Prognostic value of MIB-1 in advanced ovarian carcinoma as determined using automated immunohistochemistry and quantitative image analysis. J Surg Oncol 66:230–237CrossRefPubMed

17.

Wang K, Li D, Sun L (2016) High levels of EGFR expression in tumor stroma are associated with aggressive clinical features in epithelial ovarian cancer. Onco Targets Ther 9:377–386CrossRefPubMedPubMedCentral

18.

Masoumi-Moghaddam S, Amini A, Wei AQ, Robertson G, Morris DL (2015) Sprouty 1 predicts prognosis in human epithelial ovarian cancer. Am J Cancer Res 5:1531–1541PubMedPubMedCentral

19.

Khandakar B, Mathur SR, Kumar L, Kumar S, Datta Gupta S, Iyer VK et al (2014) Tissue biomarkers in prognostication of serous ovarian cancer following neoadjuvant chemotherapy. Biomed Res Int 401245

20.

Bachmayr-Heyda A, Aust S, Heinze G, Polterauer S, Grimm C, Braicu EI et al (2013) Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients–a study of the OVCAD consortium. BMC Cancer 13:422CrossRefPubMedPubMedCentral

21.

Heeran MC, Hogdall CK, Kjaer SK, Christensen L, Jensen A, Blaakaer J et al (2013) Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the ‘MALOVA’ ovarian cancer study. APMIS 121:1177–1186CrossRefPubMed

22.

Liu P, Sun YL, Du J, Hou XS, Meng H (2012) CD105/Ki67 coexpression correlates with tumor progression and poor prognosis in epithelial ovarian cancer. Int J Gynecol Cancer 22:586–592CrossRefPubMed

23.

Katagiri A, Nakayama K, Rahman MT, Rahman M, Katagiri H, Nakayama N et al (2012) Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. Mod Pathol 25:282–288CrossRefPubMed

24.

Aune G, Stunes AK, Tingulstad S, Salvesen O, Syversen U, Torp SH (2011) The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas. Int J Clin Exp Pathol 4:444–453PubMedPubMedCentral

25.

Kondoh E, Mori S, Yamaguchi K, Baba T, Matsumura NC, Barnett J et al (2010) Targeting slow-proliferating ovarian cancer cells. Int J Cancer 126:2448–2456PubMed

26.

Adams SF, Levine DA, Cadungog MG, Hammond R, Facciabene A, Olvera N et al (2009) Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer 115:2891–2902CrossRefPubMed

27.

Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C et al (2008) Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med V5:e232CrossRef

28.

Garcia-Velasco A, Mendiola C, Sanchez-Munoz A, Ballestin C, Colomer R, Cortes-Funes H (2008) Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma. Clin Transl Oncol 10:367–371CrossRefPubMed

29.

Tetu B, Popa I, Bairati I, L'Esperance S, Bachvarova M, Plante M et al (2008) Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas. Mod Pathol 21:1002–1010CrossRefPubMed

30.

Khouja MH, Baekelandt M, Nesland JM, Holm R (2007) The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma. Int J Gynecol Pathol 26:418–425CrossRefPubMed

31.

Yamamoto S, Tsuda H, Kita T, Maekawa K, Fujii K, Kudoh K et al (2007) Clinicopathological significance of WT1 expression in ovarian cancer: a possible accelerator of tumor progression in serous adenocarcinoma. Virchows Arch 451:27–35CrossRefPubMed

32.

Yamamoto S, Tsuda H, Yoshikawa T, Kudoh K, Kita T, Furuya K et al (2007) Clear cell adenocarcinoma associated with clear cell adenofibromatous components: a subgroup of ovarian clear cell adenocarcinoma with distinct clinicopathologic characteristics. Am J Surg Pathol 31:999–1006CrossRefPubMed

33.

Green JA, Berns EM, Coens C, Luijk I, Thompson-Hehir JV, Diest P et al (2006) Alterations in the p53 pathway and prognosis in advanced ovarian cancer: a multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865). Eur J Cancer 42:2539–2548CrossRefPubMed

34.

Surowiak P, Materna V, Kaplenko I, Spaczynski M, Dietel M, Lage H et al (2006) Topoisomerase 1A, HER/2neu and Ki67 expression in paired primary and relapse ovarian cancer tissue samples. Histol Histopathol 21:713–720PubMed

35.

Kritpracha K, Hanprasertpong J, Chandeying V, Dechsukhum C, Geater A (2005) Survival analysis in advanced epithelial ovarian carcinoma in relation to proliferative index of MIB-1 immunostaining. J Obstet Gynaecol Res 31:268–276CrossRefPubMed

36.

Elie C, Geay JF, Morcos M, Tourneau A, Girre V, Broet P et al (2004) Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group). Br J Cancer 91:470–475CrossRefPubMedPubMedCentral

37.

Camilleri-Broet S, Hardy-Bessard AC, Le Tourneau A, Paraiso D, Levrel O, Leduc B et al (2004) HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Ann Oncol 15:104–112CrossRefPubMed

38.

Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, Terakawa N (2002) Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 100:281–287PubMed

39.

Sengupta PS, McGown AT, Bajaj V, Blackhall F, Swindell R, Bromley M et al (2000) P53 and related proteins in epithelial ovarian cancer. Eur J Cancer 36:2317–2328CrossRefPubMed

40.

Costa MJ, Hansen CL, Walls JE, Scudder SA (1999) Immunohistochemical markers of cell cycle control applied to ovarian and primary peritoneal surface epithelial neoplasms: p21(WAF1/CIP1) predicts survival and good response to platinin-based chemotherapy. Hum Pathol 30:640–647CrossRefPubMed

41.

Anttila M, Kosma VM, Ji H, Wei-Ling X, Puolakka J, Juhola M et al (1998) Clinical significance of alpha-catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer. J Clin Oncol 16:2591–2600CrossRefPubMed

42.

Viale G, Maisonneuve P, Bonoldi E, Bacco A, Bevilacqua P, Panizzoni GA et al (1997) The combined evaluation of p53 accumulation and of Ki-67 (MIB1) labelling index provides independent information on overall survival of ovarian carcinoma patients. Ann Oncol V8:469–476CrossRef

43.

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al (2000) Meta analysis of observational studies in epidemiology: a proposal for reporting. Meta analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008–2012CrossRefPubMed

44.

Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L (2008) Contour-enhanced meta analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol 61:991–996CrossRefPubMed

45.

Wen S, Zhou W, Li CM, Hu J, Hu XM, Chen P et al (2015) Ki-67 as a prognostic marker in early-stage non-small cell lung cancer in Asian patients: a meta analysis of published studies involving 32 studies. BMC Cancer 15:520CrossRefPubMedPubMedCentral

46.

Pan D, Wei K, Ling Y, Su S, Zhu M, Chen G (2015) The prognostic role of Ki-67/MIB-1 in cervical cancer: a systematic review with meta analysis. Med Sci Monit 21:882–889CrossRefPubMedPubMedCentral

47.

Pyo JS, Kang G, Sohn JH (2016) Ki-67labeling index can be used as a prognostic marker in gastrointestinal stromal tumor: asystematic review and meta analysis. Int J Biol Markers 31:204–210CrossRef

Titel: High Ki-67 expression is significantly associated with poor prognosis of ovarian cancer patients: evidence from a meta-analysis
verfasst von: Dongmei Qiu
Wanqiu Cai
Zhiqiao Zhang
Hongyan Li
Dongmei Zhou
Publikationsdatum: 13.02.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 5/2019
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-019-05082-3

Neu im Fachgebiet Gynäkologie und Geburtshilfe

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

High Ki-67 expression is significantly associated with poor prognosis of ovarian cancer patients: evidence from a meta-analysis

Abstract

Objective

Methods

Results

Conclusions

Neu im Fachgebiet Gynäkologie und Geburtshilfe

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Gynäkologie

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2019

Examination of cervical swabs of patients with endometriosis using Fourier transform infrared spectroscopy

Long-term effects of prenatal exposure to metformin on the health of children based on follow-up studies of randomized controlled trials: a systematic review and meta-analysis

Comparison of the determination of the local tumor extent of primary endometrial cancer using clinical examination and 3 Tesla magnetic resonance imaging compared to histopathology

Treatment anxiety in breast cancer patients

Prevention of spontaneous preterm birth

Identification of 3q oncogene SEC62 as a marker for distant metastasis and poor clinical outcome in invasive ductal breast cancer

Neu im Fachgebiet Gynäkologie und Geburtshilfe

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Gynäkologie